<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04295681</url>
  </required_header>
  <id_info>
    <org_study_id>MMH-MAP-002</org_study_id>
    <nct_id>NCT04295681</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Cognitive Disorders in Patients With Ischemic Stroke in the Carotid Arteries</brief_title>
  <official_title>A Multicenter, Double-blind, Randomized, Parallel Group Placebo-controlled Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Cognitive Disorders in Patients With Ischemic Stroke in the Carotid Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Materia Medica Holding</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Materia Medica Holding</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical trial to valuate efficacy and safety of MMH-MAP in the treatment of cognitive&#xD;
      disorders in patients with ischemic stroke in the carotid arteries.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design: double-blind, randomized, parallel group placebo-controlled clinical study of&#xD;
      efficacy and safety of MMH-MAP in the treatment of cognitive disorders in patients with&#xD;
      ischemic stroke in the carotid arteries.&#xD;
&#xD;
      The study will enroll hospitalized subjects of either gender aged 40-75 years old with&#xD;
      verified diagnosis of ischemic stroke in the carotid arteries within 72 hours post debut&#xD;
      having moderate cognitive disorders, moderate neurological deficit.&#xD;
&#xD;
      At Visit 1 (day 1) the subject's complaints and medical history will be collected, objective&#xD;
      examination, safety laboratory tests (hematology, serum chemistry, urinalysis) will be&#xD;
      performed. The investigator will evaluate the patient's level of consciousness using The&#xD;
      Glasgow Coma Scale, intensity of cognitive disorders using The Montreal Cognitive Assessment&#xD;
      (МоСА), condition using National Institute of Health Stroke Scale (NIHSS) and The Modified&#xD;
      Rankin Scale (mRs). Concomitant therapy will be recorded and changes in cerebral CT/MRI will&#xD;
      be evaluated. If the subject meets inclusion criteria and has no exclusion criteria, he/she&#xD;
      will be randomized to MMH-MAP or Placebo group. The first dose of the study product should be&#xD;
      taken within 72 hours post stroke debut.&#xD;
&#xD;
      At Visit 2 (day 12±3, end of hospitalization period - the last day of hospitalization due to&#xD;
      the current stroke) complaints will be collected, objective examination findings will be&#xD;
      recorded, monitoring of the prescribed and concomitant therapy will be performed, treatment&#xD;
      safety, compliance and stroke severity according to NIHSS will be evaluated.&#xD;
&#xD;
      By the end of hospital therapy the subject will be switched to outpatient therapy with&#xD;
      continuation of IMP and medical assistance designed for the treatment of stroke and its&#xD;
      sequelae.&#xD;
&#xD;
      At Visit 3 (day 45±7 days) the investigator will make a phone call to the subject evaluating&#xD;
      the treatment safety.&#xD;
&#xD;
      At final Visit 4 (day 90±7 days) complaints will be collected, objective examination findings&#xD;
      will be recorded, monitoring of the prescribed and concomitant therapy will be performed,&#xD;
      treatment safety, compliance, condition according to NIHSS will be evaluated, mRs, Clinical&#xD;
      Global Impression Efficacy Index (CGI-EI) will be filled. The investigator will perform MoCA&#xD;
      testing. Safety laboratory tests (hematology, serum chemistry, urinalysis) will be carried&#xD;
      out.&#xD;
&#xD;
      Throughout the study the patient will receive the treatment approved by the decree of the RF&#xD;
      Ministry of Health dated 29.12.2012 No. 740n &quot;On approval of standard of special care in&#xD;
      cerebral infarction&quot; except for the products specified in section &quot;Forbidden concomitant&#xD;
      therapy&quot;.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average MoCA score.</measure>
    <time_frame>On the 90th day of the treatment period.</time_frame>
    <description>Montreal Cognitive Assessment Scale (The Montreal Cognitive Assessment, MoCA) will be used to identify moderate cognitive impairment, as well as to assess changes in cognitive functions during therapy. The time for MoCA is approximately 10 minutes. The maximum possible number of points is 30; 26 points or more is considered normal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in NIHSS score.</measure>
    <time_frame>On the days 12, 90 of the treatment period.</time_frame>
    <description>NIHSS Scale (National Institutes of Health Stroke Scale) is a scale for assessing the severity of neurological disorders of the acute period of ischemic stroke. The NIHSS scale involves the assessment of a neurological condition by generally accepted methods of clinical examination of reflexes, sensory organs, and the patient's level of consciousness. The results range from minimum indicators - normal or close to normal, to maximum - reflect the degree of neurological damage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with no significant disabilities.</measure>
    <time_frame>On the 90th day of the treatment period.</time_frame>
    <description>The modified Rankin scale (mRs 0-1) allows to assess the grade of disability after a stroke. The scale includes five grades of disability: from 0 to 5: 0 - no symptoms, 5 - gross disability; bedridden, fecal and urinary incontinence, need for constant assistance by medical staff.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic and side effects, efficacy index.</measure>
    <time_frame>On the 90th day of the treatment period.</time_frame>
    <description>According to Clinical Global Impression Efficacy Index (CGI-EI).CGI-EI is filled out by an investigator. It is necessary to indicate the level of efficacy of the therapy and the grade of safety of the therapy and circle the index values at the intersection of the selected lines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence and nature of adverse events (AEs).</measure>
    <time_frame>For 90 days of the treatment period.</time_frame>
    <description>Based on medical records. Occurrence, nature, severity, causality and outcome of adverse events (AEs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with сomplication of cerebral infarction.</measure>
    <time_frame>For 90 days of the treatment period.</time_frame>
    <description>Based on medical records. The sequelae of cerebral infarction (severe infections - hospital-acquired pneumonia, uroinfection; deep venous thrombosis, PATE; epileptic episodes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death rate.</measure>
    <time_frame>For 90 days of the treatment period.</time_frame>
    <description>Based on medical records. Frequency of all-cause mortality outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in vital signs (pulse rate (heart rate)).</measure>
    <time_frame>For 90 days of the treatment period.</time_frame>
    <description>Based on medical records. Vital signs will be measured in a medical setting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in vital signs (respiration rate (breathing rate)).</measure>
    <time_frame>For 90 days of the treatment period.</time_frame>
    <description>Based on medical records. Vital signs will be measured in a medical setting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in vital signs (blood pressure).</measure>
    <time_frame>For 90 days of the treatment period.</time_frame>
    <description>Based on medical records. Vital signs will be measured in a medical setting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with clinically significant abnormal laboratory data.</measure>
    <time_frame>For 90 days of the treatment period.</time_frame>
    <description>Based on medical records.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with recurring cerebral infarction.</measure>
    <time_frame>For 90 days of the treatment period.</time_frame>
    <description>Based on medical records.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">246</enrollment>
  <condition>Cognitive Disorders</condition>
  <arm_group>
    <arm_group_label>MMH-MAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration. 2 tablets twice daily (approximately at the same time). The drug is taken outside a meal (between the meals or 15 min prior to meal or fluid intake). Tablets should be held in the mouth until completely dissolved. The overall duration of treatment is 90 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral administration. For 90 days according to MMH-MAP dosing regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MMH-MAP</intervention_name>
    <description>Oral administration.</description>
    <arm_group_label>MMH-MAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 40 and 75 years old inclusively.&#xD;
&#xD;
          2. Ischemic stroke in the carotid arteries (I 63) within 72 hours post debut.&#xD;
&#xD;
          3. Moderate cognitive disorders (MoCA &lt; 26).&#xD;
&#xD;
          4. Normal consciousness (Glasgow score 15)&#xD;
&#xD;
          5. Stroke severity 8-12 according to NIHSS.&#xD;
&#xD;
          6. Disability mRs score 2-3.&#xD;
&#xD;
          7. Availability of cerebral CT/MRI within 72 hours post stroke debut.&#xD;
&#xD;
          8. Patients who agreed to use a reliable method of contraception during the study.&#xD;
&#xD;
          9. Patients who have signed the Participant Information Sheet and Informed Consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current or previous subarachnoidal/parenchymatous/ventricular hemorrhage, cerebral&#xD;
             infarction, cerebral tumour.&#xD;
&#xD;
          2. Cerebral CT/MRI findings suggesting cerebral hemorrhage, tumour within 72 hours post&#xD;
             stroke debut.&#xD;
&#xD;
          3. Scheduled or completed thrombolytic therapy for the treatment of the current cerebral&#xD;
             infarction.&#xD;
&#xD;
          4. Central nervous system (CNS) diseases including:&#xD;
&#xD;
               -  Inflammatory diseases of the central nervous system (G00-G09);&#xD;
&#xD;
               -  Systemic atrophies primarily affecting the central nervous system (G10-G13);&#xD;
&#xD;
               -  Extrapyramidal and movement disorders (G20-G26);&#xD;
&#xD;
               -  Other degenerative diseases of the nervous system (G30-G32);&#xD;
&#xD;
               -  Demyelinating diseases of the CNS (G35-G37);&#xD;
&#xD;
               -  Episodic and paroxysmal disorders (G40-G47);&#xD;
&#xD;
               -  Polyneuropathies and other disorders of the peripheral nervous system (G60-64),&#xD;
                  with marked movement and/or sensory impairments that cause movement disorders;&#xD;
&#xD;
               -  Hydrocephalus (G91).&#xD;
&#xD;
          5. (History of) injuries to the head (S00-S09) associated with impaired consciousness,&#xD;
             cerebral contusion or open craniocerebral trauma.&#xD;
&#xD;
          6. Musculoskeletal disorders causing motor disturbances.&#xD;
&#xD;
          7. (History of) dementia (F00-F03).&#xD;
&#xD;
          8. Malignant neoplasms.&#xD;
&#xD;
          9. Patients previously diagnosed with class IV heart failure (1964 New York Heart&#xD;
             Association functional classification), hypothyroidism, or poorly treated diabetes&#xD;
             mellitus.&#xD;
&#xD;
         10. Patients having unstable angina or myocardial infarction in the past 6 months.&#xD;
&#xD;
         11. Allergy/ intolerance to any of the components of medications used in the treatment.&#xD;
&#xD;
         12. Malabsorption syndrome, including congenital or acquired lactase deficiency (or any&#xD;
             other disaccharidase deficiency) and galactosemia.&#xD;
&#xD;
         13. Any conditions which, according to the investigator opinion, may interfere with the&#xD;
             subject's participation in the study.&#xD;
&#xD;
         14. Prior history of non-adherence to a drug regimen, a psychiatric disorder, alcoholism&#xD;
             or drug abuse, which, in the opinion of the investigator, can compromise compliance&#xD;
             with study protocol.&#xD;
&#xD;
         15. Pregnancy, breast-feeding; childbirth less than 3 months prior to the inclusion in the&#xD;
             trial, unwillingness to use contraceptive methods during the trial.&#xD;
&#xD;
         16. Participation in other clinical studies within 3 month prior to enrollment in the&#xD;
             study.&#xD;
&#xD;
         17. Patients who are related to any of the on-site research personnel directly involved in&#xD;
             the conduct of the trial or are an immediate relative of the study investigator.&#xD;
             'Immediate relative' means husband, wife, parent, son, daughter, brother, or sister&#xD;
             (regardless of whether they are natural or adopted).&#xD;
&#xD;
         18. Patients who work for OOO &quot;NPF &quot;Materia Medica Holding&quot; (i.e. the company's employees,&#xD;
             temporary contract workers, designated officials responsible for carrying out the&#xD;
             research or any immediate relatives of the aforementioned).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mikhail Putilovskiy, MD, PhD</last_name>
    <phone>+74952761571</phone>
    <phone_ext>302</phone_ext>
    <email>PutilovskiyMA@materiamedica.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First City Clinical Hospital named after E.E. Volosevich</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163001</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vitaliy Saskin, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Vitaliy Saskin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkhangelsk Regional Clinical Hospital/Neurological Department</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Belgorod Regional Clinical Hospital of St. Joasaph</name>
      <address>
        <city>Belgorod</city>
        <zip>308007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhanna Chefranova, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Zhanna Chefranova, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital # 3</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dmitriy Popov, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Dmitriy Popov, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kazan State Medical University/Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Enver Bogdanov, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Enver Bogdanov, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Interregional Clinical Diagnostic Center</name>
      <address>
        <city>Kazan</city>
        <zip>420101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dina Khasanova, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Dina Khasanova, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Institute - Regional Clinical Hospital # 1 named after Prof. S.V. Ochapovsky</name>
      <address>
        <city>Krasnodar</city>
        <zip>350086</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lyudmila Timchenko, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lyudmila Timchenko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital named after V.M. Buyanov, Moscow Department of Health</name>
      <address>
        <city>Moscow</city>
        <zip>115516</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel Kamchatnov, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Pavel Kamchatnov, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital of the Russian Academy of Sciences</name>
      <address>
        <city>Moscow</city>
        <zip>117593</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital # 5 of the Nizhegorodskiy District of Nizhny Novgorod</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evgeniy Pudov, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Evgeniy Pudov, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nizhny Novgorod Regional Clinical Hospital named after N. A. Semashko</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentina Nesterova, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Valentina Nesterova, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novosibirsk State Regional Clinical Hospital</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel Pilipenko, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Pavel Pilipenko, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital # 34</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630091</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elena Vostrikova, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Elena Vostrikova, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>yazan State Medical University named after acad. I.P. Pavlov/Regional Clinic Hospital</name>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vladimir Zhadnov, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Vladimir Zhadnov, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional Clinic Hospital/Emergency cardiology unit with intensive care and resuscitation unit</name>
      <address>
        <city>Ryazan</city>
        <zip>390039</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sergey Aksentyev, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Sergey Aksentyev, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Petersburg Research Institute of Ambulance named after I.I. Janelidze</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>192242</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor Voznyuk, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Igor Voznyuk, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City Multidisciplinary Hospital # 2</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantin Golikov, MD</last_name>
    </contact>
    <investigator>
      <last_name>Konstantin Golikov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samara City Clinical Hospital # 1 named after N.I. Pirogov/Neurological Department</name>
      <address>
        <city>Samara</city>
        <zip>443096</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatiana Lokshtanova, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Tatiana Lokshtanova, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saratov City Clinical Hospital # 9</name>
      <address>
        <city>Saratov</city>
        <zip>410031</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ekaterina Salina, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Ekaterina Salina, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ulyanovsk Regional Clinical Hospital/Neurological Department</name>
      <address>
        <city>Ulyanovsk</city>
        <zip>432063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irina Greshnova, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Irina Greshnova, MD, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional Clinic Hospital/Neurological department for patients with acute cerebrovascular accident</name>
      <address>
        <city>Vladimir</city>
        <zip>600023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuliya Gerasimova, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Yuliya Gerasimova, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Voronezh Regional Clinical Hospital # 1</name>
      <address>
        <city>Voronezh</city>
        <zip>394066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Svetlana Chuprina, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Svetlana Chuprina, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vsevolozhsk Clinical Interdistrict Hospital</name>
      <address>
        <city>Vsevolozhsk</city>
        <zip>188643</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liya Lukinykh, MD</last_name>
    </contact>
    <investigator>
      <last_name>Liya Lukinykh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital # 8/Intensive Care Unit</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150030</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksandr Malygin, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Aleksandr Malygin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 27, 2020</study_first_submitted>
  <study_first_submitted_qc>March 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2020</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

